Next Article in Journal
Critical Overview of the Risk Scoring Systems to Predict Non-Responsiveness to Intravenous Immunoglobulin in Kawasaki Syndrome
Next Article in Special Issue
Tamoxifen Treatment of Breast Cancer Cells: Impact on Hedgehog/GLI1 Signaling
Previous Article in Journal
Expression Patterns of Genes Involved in Ascorbate-Glutathione Cycle in Aphid-Infested Maize (Zea mays L.) Seedlings
Previous Article in Special Issue
Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessCommunication

Using Copy Number Alterations to Identify New Therapeutic Targets for Bladder Carcinoma

School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy
Medical Genetics Laboratory, San Gerardo Hospital, 20900 Monza, Italy
Department of Pathology, San Gerardo Hospital, 20900 Monza, Italy
Urology Division, Bassini Icp Hospital, 20092 Cinisello Balsamo, Italy
Author to whom correspondence should be addressed.
Academic Editor: William Chi-shing Cho
Int. J. Mol. Sci. 2016, 17(3), 271;
Received: 11 January 2016 / Revised: 17 February 2016 / Accepted: 17 February 2016 / Published: 24 February 2016
(This article belongs to the Collection Advances in Molecular Oncology)
PDF [420 KB, uploaded 24 February 2016]


Bladder cancer represents the ninth most widespread malignancy throughout the world. It is characterized by the presence of two different clinical and prognostic subtypes: non-muscle-invasive bladder cancers (NMIBCs) and muscle-invasive bladder cancers (MIBCs). MIBCs have a poor outcome with a common progression to metastasis. Despite improvements in knowledge, treatment has not advanced significantly in recent years, with the absence of new therapeutic targets. Because of the limitations of current therapeutic options, the greater challenge will be to identify biomarkers for clinical application. For this reason, we compared our array comparative genomic hybridization (array-CGH) results with those reported in literature for invasive bladder tumors and, in particular, we focused on the evaluation of copy number alterations (CNAs) present in biopsies and retained in the corresponding cancer stem cell (CSC) subpopulations that should be the main target of therapy. According to our data, CCNE1, MYC, MDM2 and PPARG genes could be interesting therapeutic targets for bladder CSC subpopulations. Surprisingly, HER2 copy number gains are not retained in bladder CSCs, making the gene-targeted therapy less interesting than the others. These results provide precious advice for further study on bladder therapy; however, the clinical importance of these results should be explored. View Full-Text
Keywords: bladder cancer; transitional cell carcinomas; therapeutic targets; cancer stem cells; copy number alterations bladder cancer; transitional cell carcinomas; therapeutic targets; cancer stem cells; copy number alterations

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Conconi, D.; Sala, E.; Bovo, G.; Strada, G.; Dalprà, L.; Lavitrano, M.; Bentivegna, A. Using Copy Number Alterations to Identify New Therapeutic Targets for Bladder Carcinoma. Int. J. Mol. Sci. 2016, 17, 271.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top